ASND - Ascendis Pharma A/S

QQQ $ 454.82 $ -0.84 (-0.19 %)

DIA $ 398.57 $ 6.05 (1.59 %)

SPY $ 530.36 $ 4.76 (0.91 %)

TLT $ 91.26 $ 0.61 (0.68 %)

GLD $ 225.37 $ -1.27 (-0.59 %)

Previous Close

$ 135.1

Open

$ 140.00

Bid

$ 134.77 x 100

Ask

$ 136.71 x 100

Day's Range

$ 134.92 - $ 143.16

52 Week Range

$ 85.08 - $ 161.00

Volume

587,045

Average Volume

Market Cap

7.8B

Beta (5Y Monthly)

$ 0.71

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

if-you-invested-100-in-this-stock-15-years-ago-you-would-have-4100-today

If You Invested $100 In This Stock 15 Year...
05/31/2024 20:30:22

Stifel Initiates Coverage On Ascendis Phar...
05/31/2024 10:03:41

Stifel analyst Alex Thompson initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Targe...

asnd---analyzing-ascendis-pharmas-short-interest

(ASND) - Analyzing Ascendis Pharma's Short...
05/28/2024 14:00:26

100-invested-in-this-stock-10-years-ago-would-be-worth-6500-today

$100 Invested In This Stock 10 Years Ago W...
05/17/2024 20:00:34

Morgan Stanley Maintains Equal-Weight on A...
05/16/2024 16:00:50

Morgan Stanley analyst Vikram Purohit maintains Ascendis Pharma (NASDAQ:ASND) with a Equal-Weight and raises the price targe...

fda-pushes-review-date-for-ascendis-pharmas-hormone-disorder-candidate-by-three-months

FDA Pushes Review Date For Ascendis Pharma...
05/15/2024 15:57:08

Ascendis Pharma announces FDA's extension of the review date for TransCon PTH for adults with hypoparathyroidism to August ...

Cantor Fitzgerald Reiterates Overweight on...
05/15/2024 12:27:24

Cantor Fitzgerald analyst Li Watsek reiterates Ascendis Pharma (NASDAQ:ASND) with a Overweight and maintains $173 price target.

FDA Extends Review Period For Ascendis Pha...
05/14/2024 18:37:24

Prescription Drug User Fee Act (PDUFA) goal date extended by three months for further review of submission to August 14, 2024

Ascendis Pharma Announces 2-Year Results F...
05/13/2024 12:37:16

Ascendis Pharma A/S (NASDAQ:ASND) today announced 2-year results from a post-hoc analysis of the Company's Phase 3 PaTHway ...

Ascendis Pharma A/S Clinical And Quality-O...
05/09/2024 13:17:12

Ascendis Pharma A/S (NASDAQ:ASND) today announced that new TransCon PTH (palopegteriparatide) data supporting clinical and qual...

100-invested-in-ascendis-pharma-15-years-ago-would-be-worth-this-much-today

$100 Invested In Ascendis Pharma 15 Years ...
05/06/2024 18:00:40

Wells Fargo Maintains Overweight on Ascend...
05/03/2024 18:03:02

Wells Fargo analyst Derek Archila maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from...

JP Morgan Maintains Overweight on Ascendis...
05/03/2024 15:19:08

JP Morgan analyst Jessica Fye maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $16...

Cantor Fitzgerald Reiterates Overweight on...
05/03/2024 14:59:37

Cantor Fitzgerald analyst Li Watsek reiterates Ascendis Pharma (NASDAQ:ASND) with a Overweight and maintains $173 price target.

Ascendis Pharma Q1 Sales €95.894M Beat €79...
05/02/2024 20:46:03

looking-into-ascendis-pharmas-recent-short-interest

Looking Into Ascendis Pharma's Recent Shor...
04/26/2024 15:30:29

MHRA Approves YORVIPATH In Great Britain F...
04/24/2024 12:31:30

Morgan Stanley Maintains Equal-Weight on A...
04/22/2024 17:15:47

Morgan Stanley analyst Vikram Purohit maintains Ascendis Pharma (NASDAQ:ASND) with a Equal-Weight and maintains $116 price t...

1000-invested-in-ascendis-pharma-15-years-ago-would-be-worth-this-much-today

$1000 Invested In Ascendis Pharma 15 Years...
04/18/2024 19:30:33

Cantor Fitzgerald Reiterates Overweight on...
04/18/2024 13:43:37

Cantor Fitzgerald analyst Li Watsek reiterates Ascendis Pharma (NASDAQ:ASND) with a Overweight and maintains $173 price target.